Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › SUPN

RICE HALL JAMES & ASSOCIATES, LLC position in SUPN

SUPERNUS PHARMACEUTICALS · Health Care

RICE HALL JAMES & ASSOCIATES, LLC reported holding 477,147 shares of SUPN (SUPERNUS PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$20.5M, representing 1.09% of its reported portfolio and ranking #32 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed SUPN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)477.15K sh
Reported value held$20.54M
Portfolio Weight1.09%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RICE HALL JAMES & ASSOCIATES, LLC's SUPN position evolved

RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in SUPN in Q3 2023 at 544,468 shares (US$15.0M). The position peaked in Q1 2026 at 477,416 shares, worth US$24.7M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 477,147 shares valued at US$20.5M — a reduction of -13,074 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 544.47K $15.01M New
Q4 2023 529.95K $15.34M Reduce
Q1 2024 516.77K $17.63M Reduce
Q2 2024 502.59K $13.44M Reduce
Q3 2024 540.79K $16.86M Add
Q4 2024 528.35K $19.10M Reduce
Q1 2025 515.89K $16.90M Reduce
Q2 2025 524.65K $16.54M Add
Q3 2025 476.08K $22.75M Reduce
Q4 2025 467.89K $23.25M Reduce
Q1 2026 477.42K $24.68M Add
Q2 2026 490.22K $22.80M Add
Q3 2026 477.15K $20.54M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SUPN and 13F data

SUPN (SUPERNUS PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in SUPN — the largest reported positions include MILLENNIUM MANAGEMENT LLC (US$179.2M), ARMISTICE CAPITAL, LLC (US$109.7M), SYSTEMATIC FINANCIAL MANAGEMENT LP (US$34.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SUPN

All SUPN fund holders →

FAQ

How long has RICE HALL JAMES & ASSOCIATES, LLC held SUPN?

RICE HALL JAMES & ASSOCIATES, LLC has disclosed SUPN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is RICE HALL JAMES & ASSOCIATES, LLC's current position in SUPN?

As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 477.15K shares of SUPN (SUPERNUS PHARMACEUTICALS), valued at $20.54M, representing 1.09% of its reported portfolio and ranking #32.

Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling SUPN?

In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in SUPN. The position peaked in Q1 2026 at 477.42K shares.

Which other funds hold SUPN?

Other major institutional holders of SUPN include MILLENNIUM MANAGEMENT LLC, ARMISTICE CAPITAL, LLC, SYSTEMATIC FINANCIAL MANAGEMENT LP, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.